$AXGN earnings report

Axogen, Inc. Reports Third Quarter 2026 Financial Results Raises Full Year Revenue Guidance to at Least 29% Growth or $290 million. AlphAI read Axogen's Third quarter 2026 filing as solid. 2 quarters are on record below.

Third quarter 2026

AlphAI · Earnings readAXGN · Third quarter 2026 · ended September 30, 2026

Axogen, Inc. Reports Third Quarter 2026 Financial Results Raises Full Year Revenue Guidance to at Least 29% Growth or $290 million

✓Solid quarter

Third-quarter revenue increased 26.2% to $75.8 million, adjusted EBITDA increased to $13.4 million, and adjusted net income increased to $13.1 million. Gross margin declined to 74.8% from 76.6%, while GAAP operating income declined to $1.0 million from $1.9 million. The company raised full-year revenue guidance to at least $290 million and continued to expect positive full-year free cash flow.

Revenue
$75.8M
26.2% y/y
Gross margin · GAAP
74.8%
Full-year 2026 outlook
at least $290 million, representing growth of at least 29%, including at least $7 million revenue from the BioCircuit acquisition
GM at least 73%

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Revenue, three months ended September 30, 2026GAAP$75.8M–26.2%
Cost of goods sold, three months ended September 30, 2026GAAP$19.10M––
Gross profit, three months ended September 30, 2026GAAP$56.73M––
Gross margin, three months ended September 30, 2026GAAP74.8%––
Sales and marketing expense, three months ended September 30, 2026GAAP$30.36M––
Research and development expense, three months ended September 30, 2026GAAP$8.95M––
General and administrative expense, three months ended September 30, 2026GAAP$16.46M––
Total costs and expenses, three months ended September 30, 2026GAAP$55.78M––
Income from operations, three months ended September 30, 2026GAAP$955K––
Investment income, three months ended September 30, 2026GAAP$1.43M––
Interest expense, three months ended September 30, 2026GAAP−$1K––
Change in fair value of debt derivative liabilities, three months ended September 30, 2026GAAP—––
Other expense, net, three months ended September 30, 2026GAAP−$51K––
Total other income (expense), net, three months ended September 30, 2026GAAP$1.38M––
Net income, three months ended September 30, 2026GAAP$2.3M––
Net income per common share, basic, three months ended September 30, 2026GAAP$0.04––
Net income per common share, diluted, three months ended September 30, 2026GAAP$0.04 per share––
EBITDA, three months ended September 30, 2026non-GAAP$2.63M––
EBITDA margin, three months ended September 30, 2026non-GAAP3.5%––
Adjusted EBITDA, three months ended September 30, 2026non-GAAP$13.4M––
Adjusted EBITDA margin, three months ended September 30, 2026non-GAAP17.7%––
Adjusted net income, three months ended September 30, 2026non-GAAP$13.1M––
Adjusted net income per common share, diluted, three months ended September 30, 2026non-GAAP$0.21 per share––
Revenue, nine months ended September 30, 2026GAAP$207.0M––
Gross profit, nine months ended September 30, 2026GAAP$153.6M––
Income (loss) from operations, nine months ended September 30, 2026GAAP−$4.03M––
Loss on extinguishment of debt, nine months ended September 30, 2026GAAP−$16.85M––
Net loss, nine months ended September 30, 2026GAAP−$18.77M––
Net loss per common share, diluted, nine months ended September 30, 2026GAAP$(0.35)––
Adjusted EBITDA, nine months ended September 30, 2026non-GAAP$27.50M––
Adjusted EBITDA margin, nine months ended September 30, 2026non-GAAP13.3%––
Adjusted net income, nine months ended September 30, 2026non-GAAP$24.45M––
Adjusted net income per common share, diluted, nine months ended September 30, 2026non-GAAP$0.41––
Net cash provided by operating activities, nine months ended September 30, 2026GAAP$25.32M––
Purchase of property and equipment, nine months ended September 30, 2026GAAP−$5.07M––
Cash payments for intangible assets, nine months ended September 30, 2026GAAP−$1.31M––
Free cash flow, nine months ended September 30, 2026non-GAAP$18.94M––

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

Full-year 2026 outlook

  • Revenueat least $290 million, representing growth of at least 29%, including at least $7 million revenue from the BioCircuit acquisition
  • Gross marginat least 73%
  • NoteOrganic revenue excluding BioCircuit: at least $283 million, representing growth of at least 26%
  • NotePositive free cash flow for the full-year

What drove it

  • Year-to-date revenue growth through the third quarter of 2026 was broad-based across Extremities, Oral Maxillofacial & Head and Neck, and Breast.
  • Management attributed year-to-date revenue growth to 20% plus year-over-year account productivity, expanding sales force coverage, and improving commercial insurance coverage and payment.
  • Axogen received positive coverage decisions from Elevance and Aetna; commercial payer coverage for Avance is now approximately 96% of covered lives in the United States.
  • The company completed the acquisition of BioCircuit Technologies, Inc. on October 1, 2026.
  • Management decided to initiate Prostate market development beginning in 2027 based on positive clinical study outcomes.

Concerns

  • Third-quarter gross margin was 74.8%, compared to 76.6% in the third quarter of 2025.
  • Third-quarter income from operations was $955 (in thousands), compared to $1,912 (in thousands) in the third quarter of 2025.
  • The nine-month period reported a GAAP net loss of $(18,766) (in thousands), including a $(16,849) (in thousands) loss on extinguishment of debt.
  • Third-quarter general and administrative expense was $16,465 (in thousands), compared to $10,836 (in thousands), and included $1,969 (in thousands) of BioCircuit transaction and integration costs in the adjusted net income reconciliation.
  • The company identified risks associated with integrating BioCircuit and realizing anticipated benefits of the acquisition.

What to watch

  • Execution against full-year revenue guidance of at least $290 million, including at least $7 million of revenue from BioCircuit.
  • Delivery of full-year gross margin of at least 73% and positive free cash flow.
  • Integration of BioCircuit and commercialization of NerveTape.
  • Progress in commercial insurance coverage and payment for peripheral nerve repair.
  • The planned initiation of Prostate market development in 2027.

Balance sheet and cash flow

  • Cash and cash equivalents as of September 30, 2026: $328,888 (in thousands), compared to $35,548 (in thousands) as of December 31, 2025.
  • Restricted cash as of September 30, 2026: $2,000 (in thousands), compared to $4,000 (in thousands) as of December 31, 2025.
  • Investments as of September 30, 2026: $19,180 (in thousands), compared to $5,980 (in thousands) as of December 31, 2025.
  • Cash and cash equivalents, restricted cash, and investments as of September 30, 2026: $350.1 million, compared to $113.4 million as of June 30, 2026, an increase of $236.7 million.
  • Long-term debt, net of debt discount and financing fees, as of September 30, 2026: —, compared to $48,387 (in thousands) as of December 31, 2025.
  • Net cash provided by financing activities for the nine months ended September 30, 2026: $292,415 (in thousands), compared to $5,933 (in thousands).
  • Proceeds from issuance of common stock for the nine months ended September 30, 2026: $359,622 (in thousands).
  • Repayment of long-term debt for the nine months ended September 30, 2026: $(48,585) (in thousands).
  • Fees paid to lender related to debt extinguishment for the nine months ended September 30, 2026: $(20,498) (in thousands).

Analysis

Axogen reported third-quarter revenue of $75.8 million, an increase of 26.2% compared to $60.1 million in the third quarter of 2025. Management described year-to-date growth as broad-based across Extremities, Oral Maxillofacial & Head and Neck, and Breast, driven by 20% plus year-over-year account productivity, expanding sales force coverage, and improving commercial insurance coverage and payment. The company also reported positive coverage decisions from Elevance and Aetna, with Avance commercial payer coverage at approximately 96% of covered lives in the United States.

Profitability was mixed on a GAAP basis. Gross margin was 74.8%, compared to 76.6% in the prior-year quarter, while income from operations was $955 (in thousands), compared to $1,912 (in thousands). Net income rose to $2.3 million from $0.7 million, supported by $1,431 (in thousands) of investment income and a reduction in interest expense to $(1) (in thousands) from $(1,757) (in thousands). Adjusted EBITDA increased to $13.4 million from $9.2 million, and adjusted EBITDA margin increased to 17.7% from 15.4%.

For the first nine months, revenue was $207,022 (in thousands), compared to $165,304 (in thousands). The period produced $25,322 (in thousands) of operating cash flow and $18,942 (in thousands) of free cash flow, compared to operating cash use of $(2,226) (in thousands) and free cash flow of $(5,862) (in thousands) in the prior-year period. GAAP net loss was $(18,766) (in thousands), including a $(16,849) (in thousands) loss on extinguishment of debt, while adjusted net income was $24,455 (in thousands).

The balance sheet changed materially following equity financing and debt extinguishment. The company reported $350.1 million of cash and cash equivalents, restricted cash, and investments as of September 30, 2026, compared to $113.4 million as of June 30, 2026. It closed an upsized public offering of 5,646,500 shares for $225 million of net proceeds, of which $200 million funded the BioCircuit acquisition and $1.9 million funded transaction-related expenses. Long-term debt was — at September 30, 2026, compared to $48,387 (in thousands) at December 31, 2025.

Management raised full-year revenue guidance to at least $290 million, representing growth of at least 29%, including at least $7 million from BioCircuit. Excluding BioCircuit, organic revenue is expected to be at least $283 million, representing growth of at least 26%. The company maintained expectations for gross margin of at least 73% and positive free cash flow for the full year. Execution on BioCircuit integration, the guided contribution from that acquisition, margin delivery, and the planned 2027 Prostate market development are the central reported milestones ahead.

Management, verbatim

We are delighted with our third-quarter and year-to-date revenue performance and the progress we continue to make across each of Axogen’s strategic plan priorities.

Michael Dale, President and CEO of Axogen, Inc.

Our strong growth across all markets, continues to validate our market development strategies and the strength of our commercial execution.

Michael Dale, President and CEO of Axogen, Inc.

We remain well positioned to achieve our 2026 revenue guidance and longer-term strategic objectives.

Michael Dale, President and CEO of Axogen, Inc.

Not in the filing

stated, not guessed
  • Revenue by reportable operating segment or market was not disclosed.
  • Quarterly operating cash flow and quarterly free cash flow were not disclosed.
  • Share repurchases and dividends were not disclosed.
  • Full-year 2026 operating-expense guidance was not disclosed.
  • Full-year 2026 tax-rate guidance was not disclosed.
  • The previous outlook covered the full year 2026 only, so there is nothing to compare for this quarter.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Second quarter 2026

AlphAI · Earnings readAXGN · Second quarter 2026 · ended June 30, 2026

Axogen, Inc. Reports Second Quarter 2026 Financial Results Raises Full Year Revenue Guidance to at Least 24% Growth or $279 million

→Mixed quarter

Revenue increased 23.1% and the company raised full-year revenue guidance, but gross margin declined, GAAP results moved to a net loss, and Adjusted EBITDA decreased from the prior-year quarter.

Revenue
$69.7M
23.1% y/y
Gross margin · GAAP
72.7%
EPS · non-GAAP
$0.12
2026 outlook
full-year revenue growth to be at least 24%, or revenue of at least $279 million
GM at least 73%

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
RevenueGAAP$69.7M–23.1%
Gross marginGAAP72.7%––
Net lossGAAP$1.5M––
Net loss per shareGAAP$0.03 per share––
Adjusted net incomenon-GAAP$7.3M––
Adjusted net income per sharenon-GAAP$0.12 per share––
Adjusted EBITDAnon-GAAP$8.4M––
Six Months RevenueGAAP$131.2M––
Cost of goods soldGAAP$19.06M––
Gross profitGAAP$50.67M––
Sales and marketing expenseGAAP$30.83M––
Research and development expenseGAAP$8.59M––
General and administrative expenseGAAP$13.41M––
Total costs and expensesGAAP$52.83M––
Loss from operationsGAAP−$2.16M––
Investment incomeGAAP$786K––
Interest expenseGAAP−$1K––
Other expense, netGAAP−$145K––
Total other income (expense), netGAAP$640K––
Six Months Cost of goods soldGAAP$34.33M––
Six Months Gross profitGAAP$96.86M––
Six Months Sales and marketing expenseGAAP$59.46M––
Six Months Research and development expenseGAAP$16.11M––
Six Months General and administrative expenseGAAP$26.29M––
Six Months Total costs and expensesGAAP$101.9M––
Six Months Loss from operationsGAAP−$4.99M––
Six Months Investment incomeGAAP$1.55M––
Six Months Interest expenseGAAP−$695K––
Six Months Loss on extinguishment of debtGAAP−$16.85M––
Six Months Change in fair value of debt derivative liabilitiesGAAP—––
Six Months Other expense, netGAAP−$122K––
Six Months Total other expense, netGAAP−$16.11M––
Cash and cash equivalents, restricted cash, and investmentsGAAP$113.4Man increase of $9.8 million–

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

2026 outlook

  • Revenuefull-year revenue growth to be at least 24%, or revenue of at least $279 million
  • Gross marginat least 73%
  • Notepositive free cash flow for the full-year

What drove it

  • Year-to-date revenue growth through the second quarter of 2026 was broad-based across Extremities, Oral Maxillofacial & Head and Neck, and Breast.
  • The company cited 20% plus year-over-year account productivity, expanding sales force coverage, and improving commercial insurance coverage and payment as drivers of year-to-date growth.
  • Gross margin performance was driven by changes in product mix caused primarily by accelerating year over year Breast growth greater than 50%.
  • The company published REPOSE, a prospective, randomized clinical study evaluating Axoguard Nerve Cap for symptomatic neuroma management.
  • The company initiated Nerve-RESTORE, a prospective, randomized, assessor-blinded study comparing Avance Nerve Graft to sural nerve autograft in mixed and motor nerve reconstruction.
  • The company acquired a minority ownership stake in Trace Biosciences, including a limited right of first refusal, to support development of its nerve-specific imaging technology.

Concerns

  • Gross margin was 72.7% compared to 74.2% in the second quarter of 2025.
  • The company reported a net loss of $1.5 million compared to net income of $0.6 million in the second quarter of 2025.
  • Loss from operations was $(2,156) (in thousands) compared to income from operations of $1,672 (in thousands) in the second quarter of 2025.
  • Adjusted EBITDA was $8.4 million compared to $9.3 million in the second quarter of 2025.
  • Six-month results included a loss on extinguishment of debt of $(16,849) (in thousands).

What to watch

  • Execution toward full-year revenue growth of at least 24%, or revenue of at least $279 million.
  • Ability to deliver gross margin of at least 73% for 2026 following second-quarter gross margin of 72.7%.
  • Delivery of positive free cash flow for the full-year.
  • Sustained growth across Extremities, Oral Maxillofacial & Head and Neck, and Breast.
  • Commercial progress from sales force coverage expansion and improving commercial insurance coverage and payment.
  • Development of the Nerve-RESTORE study and Trace Biosciences nerve-specific imaging technology.

Balance sheet and cash flow

  • Cash and cash equivalents: $94,572 (in thousands) as of June 30, 2026; $35,548 (in thousands) as of December 31, 2025.
  • Restricted cash: $2,000 (in thousands) as of June 30, 2026; $4,000 (in thousands) as of December 31, 2025.
  • Investments: $16,840 (in thousands) as of June 30, 2026; $5,980 (in thousands) as of December 31, 2025.
  • Accounts receivable, net of allowance for doubtful accounts of $734 and $948, respectively: $34,126 (in thousands) as of June 30, 2026; $26,169 (in thousands) as of December 31, 2025.
  • Inventory: $47,313 (in thousands) as of June 30, 2026; $42,373 (in thousands) as of December 31, 2025.
  • Total current assets: $200,376 (in thousands) as of June 30, 2026; $120,422 (in thousands) as of December 31, 2025.
  • Total assets: $304,863 (in thousands) as of June 30, 2026; $221,687 (in thousands) as of December 31, 2025.
  • Long-term debt, net of debt discount and financing fees: — as of June 30, 2026; $48,387 (in thousands) as of December 31, 2025.
  • Total liabilities: $48,606 (in thousands) as of June 30, 2026; $92,840 (in thousands) as of December 31, 2025.
  • Total shareholders’ equity: $256,257 (in thousands) as of June 30, 2026; $128,847 (in thousands) as of December 31, 2025.

Analysis

Second-quarter revenue was $69.7 million, an increase of 23.1% compared with $56.7 million in the second quarter of 2025. The company described year-to-date growth as broad-based across Extremities, Oral Maxillofacial & Head and Neck, and Breast, supported by 20% plus year-over-year account productivity, expanding sales force coverage, and improving commercial insurance coverage and payment. Breast was the principal product-mix factor cited, with accelerating year-over-year growth greater than 50%.

Growth did not translate into improved reported profitability. Gross margin was 72.7%, compared with 74.2% in the second quarter of 2025, with the company attributing the change to product mix. Loss from operations was $(2,156) (in thousands), compared with income from operations of $1,672 (in thousands), and GAAP results were a net loss of $1.5 million, or $0.03 per share, compared with net income of $0.6 million, or $0.01 per share.

Non-GAAP profitability presented a different view but also showed pressure in Adjusted EBITDA. Adjusted net income was $7.3 million, compared with $5.7 million, while adjusted net income per share was unchanged at $0.12 per share. Adjusted EBITDA was $8.4 million, below $9.3 million in the prior-year quarter. For the six months ended June 30, 2026, the company recorded a loss on extinguishment of debt of $(16,849) (in thousands), and the balance sheet showed long-term debt, net of debt discount and financing fees, of — as of June 30, 2026 compared with $48,387 (in thousands) as of December 31, 2025.

Liquidity increased during the quarter. Cash and cash equivalents, restricted cash, and investments were $113.4 million as of June 30, 2026, compared with $103.6 million as of March 31, 2026, an increase of $9.8 million. The company expects positive free cash flow for the full-year, although it did not provide an actual quarterly free-cash-flow figure in the supplied text.

Management raised 2026 revenue guidance to full-year revenue growth of at least 24%, or revenue of at least $279 million. It also expects gross margin of at least 73% and positive free cash flow for the full-year. The key operating issue is whether commercial growth and the stated improvement in coverage and payment can support the full-year revenue objective while restoring gross margin above the second-quarter level and improving operating profitability.

Management, verbatim

We are pleased with our second-quarter revenue performance and the progress we’re making across each of Axogen’s strategic plan priorities. Our strong growth across all our target markets, continues to reinforce the relevance of our market development strategies and the strength of our commercial execution. We remain well positioned to achieve our revenue guidance and continue advancing our strategic objectives for 2026.

Michael Dale, President and CEO of Axogen, Inc.

Not in the filing

stated, not guessed
  • Prior outlook was not provided, so comparison of actual results with prior guidance is unavailable.
  • Segment revenue by Extremities, Oral Maxillofacial & Head and Neck, and Breast was not provided.
  • Prior-quarter revenue, gross margin, operating income, net income, EPS, adjusted net income, and Adjusted EBITDA were not provided.
  • Actual operating cash flow, capital expenditures, and free cash flow for the quarter were not provided in the supplied text.
  • Capital returns, including share repurchases and dividends, were not provided.
  • The supplied statement of operations is truncated after the beginning of the net income line; detailed GAAP net loss, income tax, weighted-average shares, and six-month net income and EPS table lines are unavailable.
  • Guidance for operating expenses and tax rate was not provided.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about AXGN earnings dates

When is Axogen's next earnings date?
AlphAI has no date for AXGN yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.